 |
9 Diseases |  |
0 Trials |
|
0 Trials |  |
160 News |  |
| «123 |
- | lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Biomarker, New P1 trial: A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers (clinicaltrials.gov) - Dec 5, 2013
P1, N=40, Recruiting, Sponsor: AstraZeneca
- || lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Biomarker, Enrollment change: A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects (clinicaltrials.gov) - Aug 25, 2013
P1, N=72, Completed, Sponsor: AstraZeneca
N=96 --> 72
- ||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Biomarker, Trial completion: A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects (clinicaltrials.gov) - Aug 25, 2013
P1, N=72, Completed, Sponsor: AstraZeneca
N=96 --> 72 Recruiting --> Completed
- | lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Biomarker, New P1 trial: A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients (clinicaltrials.gov) - Feb 18, 2013
P1, N=47, Completed, Sponsor: AstraZeneca
- ||| lanabecestat (AZD3293) / AstraZeneca, Eli Lilly
Biomarker, New P1 trial: A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects (clinicaltrials.gov) - Nov 29, 2012
P1, N=72, Completed, Sponsor: AstraZeneca